Flexion Therapeutics, Inc. (NASDAQ:FLXN) insider Neil Bodick acquired 2,700 shares of Flexion Therapeutics stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average cost of $24.49 per share, with a total value of $66,123.00. Following the completion of the purchase, the insider now owns 64,605 shares in the company, valued at approximately $1,582,176.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) traded up $0.08 on Wednesday, reaching $23.49. The company’s stock had a trading volume of 951,965 shares, compared to its average volume of 831,054. The company has a current ratio of 12.93, a quick ratio of 12.93 and a debt-to-equity ratio of 0.87. Flexion Therapeutics, Inc. has a 12-month low of $15.96 and a 12-month high of $32.25.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/flexion-therapeutics-inc-flxn-insider-neil-bodick-purchases-2700-shares/1720496.html.

Several equities research analysts recently issued reports on the company. Northland Securities reissued a “buy” rating and issued a $40.00 price objective on shares of Flexion Therapeutics in a research note on Friday, November 10th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 1st. Wells Fargo & Company set a $39.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 30th. Royal Bank Of Canada set a $44.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Sunday, October 29th. Finally, ValuEngine downgraded Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Flexion Therapeutics currently has an average rating of “Buy” and an average target price of $98.33.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FLXN. Parametric Portfolio Associates LLC grew its holdings in Flexion Therapeutics by 79.0% in the 1st quarter. Parametric Portfolio Associates LLC now owns 27,600 shares of the specialty pharmaceutical company’s stock valued at $743,000 after buying an additional 12,181 shares during the last quarter. Teachers Advisors LLC grew its holdings in Flexion Therapeutics by 3.1% in the 1st quarter. Teachers Advisors LLC now owns 44,796 shares of the specialty pharmaceutical company’s stock valued at $1,205,000 after buying an additional 1,328 shares during the last quarter. Vanguard Group Inc. grew its holdings in Flexion Therapeutics by 3.4% in the 1st quarter. Vanguard Group Inc. now owns 995,321 shares of the specialty pharmaceutical company’s stock valued at $26,784,000 after buying an additional 32,479 shares during the last quarter. Geode Capital Management LLC grew its holdings in Flexion Therapeutics by 9.3% in the 1st quarter. Geode Capital Management LLC now owns 204,357 shares of the specialty pharmaceutical company’s stock valued at $5,499,000 after buying an additional 17,318 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in Flexion Therapeutics by 4.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 100,701 shares of the specialty pharmaceutical company’s stock valued at $2,710,000 after buying an additional 4,617 shares during the last quarter. 68.95% of the stock is currently owned by hedge funds and other institutional investors.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.